This was the rationale for testing the impact of the anti-CD22 monoclonal antibody, epratuzumab, in SLE, since it was thought that CD22 engagement would impose negative regulation of BCR signaling (14). The gene discussed is BCR; the disease is systemic lupus erythematosus.